ACADIA PHARMACEUTICALS INC (ACAD)

Company Profile

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The company is headquartered in San Diego, California and currently employs 580 full-time employees. The company went IPO on 2004-05-27. Its clinical-stage development are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis and neuropsychiatric symptoms in central nervous system disorders. Its pipeline includes NUPLAZID, Trofinetide, ACP-204 and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a treatment for Parkinson's Disease Psychosis. Trofinetide is a treatment for Rett Syndrome. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. ACP-204 is a treatment for Alzheimer’s Disease Psychosis. The company also owns rights to NNZ-2591 in both Rett and Fragile X syndrome.

Company Info

ACADIA PHARMACEUTICALS INC

12830 El Camino Real, Suite 400

San Diego CALIFORNIA 92130

P: 18585582871

CEO: Stephen R. Davis

Employees: 580

Website: https://acadia.com/